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mTOR is a serine–threonine kinase belonging to the PIKK family and
acts as a central node to integrate signalling from growth and stress
factors to regulate cell growth. Other members of the PIKK family are
ATM,ATR andDNA-PKcs, which all have established roles in theDNA
damage response. mTOR is the catalytic component of functionally
distinct complexes mTORC1 and mTORC2. Recent data show that
mTORC2 complex also has tyrosine kinase activity. Dysregulation of
mTOR signalling occurs in numerous cancers, particularly in breast
cancer, leading to the use of mTORC1 inhibitors such as the rapamycin
analogue (rapalog), everolimus, for advancedhormone receptor-positive,
HER2-negative breast cancer in combinationwith exemestane. There are
manyongoing clinical trials of rapalogs in combination therapy including
DNA-damaging agents to treat breast cancer as well as mTOR kinase
inhibitors that target both mTORC1 and mTORC2 complexes. Using
breast cancer cell lines and biochemical methods, we have recently
demonstrated that there is significant crosstalk between the nutrient and
stress sensing mTOR pathway and the DNA damage response activation
ofATR/Chk1.We recently demonstrated thatDNAdamage-induced cell
cycle arrest at S and G2/M phase is dependent on mTOR. Specifically,
mTORC2 was required for the activation of Chk1, a key cell cycle reg-
ulator, at the level of Chk1 protein production. Furthermore, in a panel of
breast cancer cell lines, with varying degrees of chemoresistance, an
mTOR kinase inhibitor was able to overcome resistance to DNA-dam-
aging agents by potentially destabilising cell cycle arrest and thereby
enhancing DNA damage-induced cell death. These data suggest that
mTORC2-Chk1 signalling is a survival pathway in breast cancer which
has important implications for breast cancer combination therapy.
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